For decades, cisplatin-based chemotherapy has been the standard first-line treatment for muscle-invasive and metastatic bladder cancer — a disease with stubbornly poor long-term survival rates. A phase III trial published in the New England Journal of Medicine now challenges that entrenched standard, potentially reshaping how oncologists approach newly diagnosed patients who are actually candidates for aggressive chemotherapy.
The trial evaluated the combination of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, paired with the PD-1 checkpoint inhibitor pembrolizumab, versus conventional cisplatin-based regimens in patients with bladder cancer who were deemed cisplatin-eligible — a population historically excluded from earlier EV-pembrolizumab investigations that focused on cisplatin-ineligible or pretreated patients. The study, appearing in NEJM Volume 395, Issue 4 (July 2026), reports outcomes across a meaningful patient cohort, with efficacy data on survival and response endpoints sufficient to draw practice-relevant conclusions, though specific hazard ratios and median survival figures warrant direct review in the source publication.
This finding carries considerable weight in the oncology landscape. EV-pembrolizumab already received FDA approval for cisplatin-ineligible metastatic urothelial carcinoma based on the EV-302/KEYNOTE-869 data, demonstrating superior progression-free and overall survival versus platinum-based chemotherapy in that population. Extending that benefit to cisplatin-eligible patients — those with better baseline organ function and historically better chemotherapy outcomes — would represent a meaningful paradigm shift rather than incremental refinement. The mechanistic rationale is sound: Nectin-4 is broadly expressed in urothelial tumors, and combining targeted cytotoxicity with immune checkpoint blockade addresses both tumor-intrinsic and immune-evasion mechanisms simultaneously. Key limitations to consider include duration of follow-up, toxicity burden relative to chemotherapy (EV carries neuropathy and skin toxicity risks), and whether benefit is uniform across molecular subtypes. This trial, if its results are as robust as early signals suggest, could make EV-pembrolizumab the new universal first-line standard in urothelial carcinoma.